Published in Mol Cancer Ther on November 01, 2008
TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer (2010) 1.73
Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells. PLoS Biol (2015) 1.51
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol (2011) 1.32
Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk. Genes Cancer (2013) 1.28
Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics (2009) 1.22
Selective inhibition of human brain tumor cells through multifunctional quantum-dot-based siRNA delivery. Angew Chem Int Ed Engl (2010) 1.09
Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling. PLoS Comput Biol (2013) 1.06
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro Oncol (2013) 1.05
Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One (2012) 1.00
Modeling glioma growth and invasion in Drosophila melanogaster. Neoplasia (2009) 0.94
Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. Oncotarget (2016) 0.78
Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells. Stem Cells Dev (2014) 0.76
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell (1996) 10.83
Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell (1995) 8.75
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol (2007) 7.34
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol (2003) 3.67
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res (1995) 3.04
Targeted molecular therapy of GBM. Brain Pathol (2003) 3.02
The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther (1999) 2.89
Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol (1999) 2.75
Cadherin switch in tumor progression. Ann N Y Acad Sci (2004) 2.71
Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem (2007) 2.67
Increasing complexity of the Ras signaling pathway. J Biol Chem (1998) 2.56
"Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res (2006) 2.30
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol (2001) 2.08
Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J (2003) 1.84
A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn J Cancer Res (1990) 1.83
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res (1993) 1.82
Cadherin-mediated cellular signaling. Curr Opin Cell Biol (2003) 1.80
The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci (1999) 1.77
EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis (1996) 1.57
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A (2003) 1.56
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 1.52
Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ (2000) 1.48
Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene (1996) 1.45
Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia (2007) 1.37
Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett (1998) 1.36
Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation. J Biol Chem (2000) 1.28
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer (2004) 1.28
The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys (2004) 1.27
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer (1995) 1.27
Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem (1996) 1.20
RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene (2005) 1.16
EGF receptor amplification and expression in human brain tumours. Eur J Cancer (1992) 1.12
Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol Histopathol (1999) 1.11
Gene therapy for arthritis: what next? Arthritis Rheum (2006) 0.95
RNA interference and potential applications. Curr Top Med Chem (2006) 0.94
Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer (2003) 0.93
RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases. Biotechniques (2006) 0.88
Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res (1992) 0.87
EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep (2007) 0.86
In vivo gene delivery by lentiviral vectors. Thromb Haemost (1999) 0.81
A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol (2002) 0.77
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest (2002) 4.38
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol (2008) 3.02
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer. Ann Thorac Surg (2007) 2.34
miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest (2013) 2.11
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest (2004) 1.89
Selective transport of cytokine-induced neutrophil chemoattractant from the lung to the blood facilitates pulmonary neutrophil recruitment. Am J Physiol Lung Cell Mol Physiol (2003) 1.86
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
The pathogenesis of mesothelioma. Semin Oncol (2002) 1.80
Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity. Ann Thorac Surg (2008) 1.77
Obesity induces functional astrocytic leptin receptors in hypothalamus. Brain (2009) 1.72
Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci (2002) 1.70
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell (2004) 1.67
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. Endocrinology (2006) 1.58
Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci (2003) 1.58
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res (2005) 1.52
Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta (2011) 1.52
Blood outgrowth endothelial cell migration and trapping in vivo: a window into gene therapy. Transl Res (2009) 1.50
p300 in prostate cancer proliferation and progression. Cancer Res (2003) 1.50
Androgen regulation of gene expression. Adv Cancer Res (2010) 1.47
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol (2007) 1.44
Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem (2006) 1.43
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res (2009) 1.39
Soluble receptor inhibits leptin transport. J Cell Physiol (2008) 1.37
Functional myogenic engraftment from mouse iPS cells. Stem Cell Rev (2011) 1.35
FOXO factors: a matter of life and death. Future Oncol (2006) 1.35
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res (2007) 1.34
Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience. Radiology (2007) 1.33
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
Assessment of the myogenic stem cell compartment following transplantation of Pax3/Pax7-induced embryonic stem cell-derived progenitors. Stem Cells (2011) 1.29
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci U S A (2002) 1.28
The fasting polypeptide FGF21 can enter brain from blood. Peptides (2007) 1.26
FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest (2010) 1.25
PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res (2003) 1.23
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23
TransMiner: mining transitive associations among biological objects from text. J Biomed Sci (2004) 1.22
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther (2005) 1.21
Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem (2004) 1.20
Cerebral interleukin-15 shows upregulation and beneficial effects in experimental autoimmune encephalomyelitis. J Neuroimmunol (2010) 1.20
Convergent trafficking pattern of leptin after endocytosis mediated by ObRa-ObRd. J Cell Physiol (2007) 1.20
Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res (2013) 1.20
Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res (2007) 1.19
Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage (2008) 1.19
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol (2002) 1.18
The role of androgens and the androgen receptor in prostate cancer. Cancer Lett (2002) 1.18
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol (2012) 1.16
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res (2009) 1.15
Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol (2004) 1.15
Oncology outpatient and provider responses to a computerized symptom assessment system. Oncol Nurs Forum (2008) 1.14
Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol (2009) 1.14
Gamma glutamyl transpeptidase is a dynamic indicator of endothelial response to stroke. Exp Neurol (2006) 1.13
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res (2006) 1.13
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neurooncol (2009) 1.11
Translational control: a target for cancer therapy. Cancer Lett (2007) 1.11
IL-15 receptor deletion results in circadian changes of locomotor and metabolic activity. J Mol Neurosci (2009) 1.10
Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging (2005) 1.10
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res (2005) 1.10
Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res (2006) 1.10
Lung cancer and lung transplantation: a review. J Thorac Oncol (2009) 1.10
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg (2011) 1.09
Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate (2007) 1.09
Essential role of interleukin-15 receptor in normal anxiety behavior. Brain Behav Immun (2010) 1.09
TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets (2003) 1.08
The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr (2002) 1.08
Leptin receptor mRNA in rat brain astrocytes. Peptides (2009) 1.08
Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg (2002) 1.08
Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology (2009) 1.08
Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity? Endocrinology (2006) 1.07
Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res (2004) 1.07
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Quantification of colorectal cancer micrometastases in lymph nodes by nested and real-time reverse transcriptase-PCR analysis for carcinoembryonic antigen. Clin Cancer Res (2004) 1.06
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer (2008) 1.06
Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene (2004) 1.06
Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett (2003) 1.06
Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer (2005) 1.05
Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer J (2003) 1.05
Role of monocyte chemoattractant protein-1 (MCP-1/CCL2) in migration of neural progenitor cells toward glial tumors. J Neurosci Res (2009) 1.04